Ibandronic acid is a potent, nitrogen-containing bisphosphonate that acts as a selective inhibitor of osteoclast-mediated bone resorption. It is indicated for the treatment and prevention of postmenopausal osteoporosis. The 150mg tablet is administered as a once-monthly oral dose, offering improved convenience and adherence compared to daily or weekly regimens. It is poorly absorbed orally and must be taken on an empty stomach with plain water only.
Adult: 150 mg orally, once every month.
Note: 1. Take immediately upon rising for the day. 2. Swallow ONE 150mg tablet whole with a full glass (180-240 mL) of PLAIN WATER only. 3. Do not take with mineral water, coffee, tea, juice, or milk. 4. Do not chew or suck the tablet. 5. Remain upright (sitting or standing, do not lie down) for at least 60 minutes after taking the tablet. 6. Wait at least 60 minutes after taking the tablet before eating, drinking (anything other than water), or taking any other oral medication, including calcium and antacids.
Ibandronic acid binds with high affinity to hydroxyapatite crystals in bone mineral matrix, particularly at sites of active bone resorption. It is internalized by osteoclasts during the resorption process. Inside the osteoclast, it inhibits the enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway.
Pregnancy: Category C: Not indicated for use in women of childbearing potential. Animal studies have shown fetal skeletal abnormalities. Risk of hypocalcemia in the pregnant mother. Use only if potential benefit justifies potential fetal risk.
Driving: No known effects. However, patients who experience dizziness, vertigo, or severe bone/joint/muscle pain should exercise caution.
| Calcium Supplements / Antacids (Calcium carbonate, Aluminum/Magnesium hydroxide) | Severely reduce absorption of ibandronic acid. | Major |
| Iron Supplements / Multivitamins with Minerals | Significantly reduce absorption. Must be taken at a different time of day. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | May increase risk of gastrointestinal irritation and ulceration. | Moderate |
| Aminoglycosides (e.g., Gentamicin) | May have additive hypocalcemic effect. | Moderate |
| Loop Diuretics (e.g., Furosemide) | May increase risk of hypocalcemia. | Moderate |